Results 261 to 270 of about 1,438,336 (335)

Production of a nutrient enriched biochar: a techno‐economic feasibility analysis

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract A techno‐economic feasibility analysis was conducted for a biomass pyrolysis plant that utilized Eucalyptus to produce fertilizer‐enriched biochar. Key parameters – biomass throughput, fertilizer loading, and selling price – were optimized for financial viability using net present value (NPV), internal rate of return (IRR), return on ...
Brendon Trollip, Ryan David Merckel
wiley   +1 more source

Taxation: Federal Income Tax: Commission Received by Life Insurance Agent on Policies Purchased by Him Held to Be Taxable Income

, 1959
Roger W. Findley
openalex   +2 more sources

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E. McGuire, Patrick Gillespie, Laurence J. Egan   +7 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Savings Bank Life Insurance

, 1965
Daniel P. Kedzie, Donald R. Johnson
openalex   +2 more sources

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Electronic medicine management systems in developing countries: A landscape review

British Journal of Clinical Pharmacology, EarlyView.
Medicines are a major global health expense. However, suboptimal use increases costs and causes patient harm. One way to reduce costs and increase safe, efficient medicines use is with electronic medicines management systems (EMMS). They allow easy capture of routine health data which can facilitate research, service planning and reimbursement ...
Andrew Lambarth, Dalia Wainwright, Trisha Saha, Millicent Banks, Iona Minty, P.A.M.K. Abeywickrama, Reya V. Shah, Yogini Jani, Reecha Sofat   +8 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population

, 2020
Rigatti SJ, Stout R.
europepmc   +1 more source